Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2024

Open Access 01-12-2024 | Acute Kidney Injury | Review

Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment

Authors: Yanyan Li, Junda Wang

Published in: BMC Nephrology | Issue 1/2024

Login to get access

Abstract

Contrast-induced acute kidney injury (CI-AKI) has become the third leading cause of hospital-acquired AKI, which seriously threatens the health of patients. To date, the precise pathogenesis of CI-AKI has remained not clear and may be related to the direct cytotoxicity, hypoxia and ischemia of medulla, and oxidative stress caused by iodine contrast medium, which have diverse physicochemical properties, including cytotoxicity, permeability and viscosity. The latest research shows that microRNAs (miRNAs) are also involved in apoptosis, pyroptosis, and autophagy which caused by iodine contrast medium (ICM), which may be implicated in the pathogenesis of CI-AKI. Unfortunately, effective therapy of CI-AKI is very limited at present. Therefore, effective prevention of CI-AKI is of great significance, and several preventive options, including hydration, antagonistic vasoconstriction, and antioxidant drugs, have been developed. Here, we review current knowledge about the features of iodine contrast medium, the definition, pathogenesis, molecular mechanism, risk factors, prevention and treatment of CI-AKI.
Literature
1.
2.
Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. EUR HEART J. 2012;33(16):2007–15.PubMedCrossRef
3.
Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, Ommen VV, Wildberger JE. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017;389(10076):1312–22.PubMedCrossRef
4.
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. NEPHRON. 2012;120(4):c179–84.PubMed
5.
van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin MF, Bertolotto M, Clement O, Heinz-Peer G, Stacul F, Webb J, et al. Post-contrast acute kidney injury - part 1: definition, clinical features, incidence, role of contrast medium and risk factors: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. EUR RADIOL. 2018;28(7):2845–55.PubMedPubMedCentralCrossRef
6.
Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. RADIOLOGY 2020, 294(3):660–668.
7.
Lameire N, Kellum JA. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (part 2). CRIT CARE. 2013;17(1):205.PubMedPubMedCentralCrossRef
8.
van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin MF, Bertolotto M, Clement O, Heinz-Peer G, Stacul F, Webb J, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. EUR RADIOL. 2018;28(7):2856–69.PubMedPubMedCentralCrossRef
9.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. NEW ENGL J MED. 2016;375(4):323–34.PubMedCrossRef
10.
Stratta P, Quaglia M, Airoldi A, Aime S. Structure-function relationships of iodinated contrast media and risk of nephrotoxicity. CURR MED CHEM. 2012;19(5):736–43.PubMedCrossRef
11.
Spampinato MV, Abid A, Matheus MG. Current Radiographic Iodinated contrast agents. MAGN RESON IMAGING C. 2017;25(4):697–704.CrossRef
12.
Thomsen HS, Morcos SK. Prevention of generalized reactions to CM. ACAD RADIOL. 2002;9(Suppl 2):S433–5.PubMedCrossRef
13.
Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, Almen T, Aspelin P, Bellin MF, Clement O, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. EUR RADIOL. 2011;21(12):2527–41.PubMedCrossRef
14.
15.
Chen Y, Chen J, Fu G, Du Z, Fang Q, Cui L, et al. Chinese expert consensus on adverse reactions related to iodide contrast angiography. Chin J Intervention Cardiol. 2014;22(06):341–8.
16.
Mehta RL, Cerda J, Burdmann EA, Tonelli M, Garcia-Garcia G, Jha V, Susantitaphong P, Rocco M, Vanholder R, Sever MS, et al. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. 2015;385(9987):2616–43.PubMedCrossRef
17.
Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J AM COLL CARDIOL. 2004;44(9):1763–71.PubMedCrossRef
18.
Chandiramani R, Cao D, Nicolas J, Mehran R. Contrast-induced acute kidney injury. CARDIOVASC INTERV TH. 2020;35(3):209–17.CrossRef
19.
Azzalini L, Spagnoli V, Ly HQ. Contrast-Induced Nephropathy: from pathophysiology to preventive strategies. CAN J CARDIOL. 2016;32(2):247–55.PubMedCrossRef
20.
Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JN, Perkins RM. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. KIDNEY INT. 2012;81(5):477–85.PubMedCrossRef
21.
Moos SI, van Vemde DN, Stoker J, Bipat S. Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. EUR J RADIOL. 2013;82(9):e387–99.PubMedCrossRef
22.
Kooiman J, Pasha SM, Zondag W, Sijpkens YW, van der Molen AJ, Huisman MV, Dekkers OM. Meta-analysis: serum creatinine changes following contrast enhanced CT imaging. EUR J RADIOL. 2012;81(10):2554–61.PubMedCrossRef
23.
Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113(14):1799–806.PubMedCrossRef
24.
Azzalini L. The clinical significance and management implications of chronic total occlusion Associated with Surgical Coronary Artery Revascularization. CAN J CARDIOL. 2016;32(11):1286–9.PubMedCrossRef
25.
Scharnweber T, Alhilali L, Fakhran S. Contrast-Induced Acute kidney Injury: pathophysiology, manifestations, Prevention, and management. MAGN RESON IMAGING C. 2017;25(4):743–53.CrossRef
26.
Kusirisin P, Chattipakorn SC, Chattipakorn N. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches. J TRANSL MED. 2020;18(1):400.PubMedPubMedCentralCrossRef
27.
Heyman SN, Rosen S, Khamaisi M, Idee JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. INVEST RADIOL. 2010;45(4):188–95.PubMedCrossRef
28.
Hardiek K, Katholi RE, Ramkumar V, Deitrick C. Proximal tubule cell response to radiographic contrast media. AM J PHYSIOL-RENAL. 2001;280(1):F61–70.CrossRef
29.
McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, Mehta A. Contrast-Induced Acute kidney Injury. J AM COLL CARDIOL. 2016;68(13):1465–73.PubMedCrossRef
30.
Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. KIDNEY INT. 2003;64(1):128–39.PubMedCrossRef
31.
Liu GL, Lei R, Duan SB, Tang MM, Luo M, Xu Q. Atorvastatin alleviates iodinated contrast media-induced cytotoxicity in human proximal renal tubular epithelial cells. EXP THER MED. 2017;14(4):3309–13.PubMedPubMedCentralCrossRef
32.
Sendeski MM. Pathophysiology of renal tissue damage by iodinated contrast media. CLIN EXP PHARMACOL P. 2011;38(5):292–9.CrossRef
33.
Huang S, Tang Y, Liu T, Zhang N, Yang X, Yang D, Hong G. A novel antioxidant protects against contrast Medium-Induced Acute kidney Injury in rats. FRONT PHARMACOL. 2020;11:599577.PubMedPubMedCentralCrossRef
34.
Ward DB, Brown KC, Valentovic MA. Radiocontrast Agent Diatrizoic Acid induces Mitophagy and oxidative stress via Calcium Dysregulation. INT J MOL SCI 2019, 20(17).
35.
Hu C, Zhou G, Liu K, Yin W, Zhou L, Wang J, Chen L, Zuo S, Xie Y, Zuo X. CaMKII as a key regulator of contrast-induced nephropathy through mPTP opening in HK-2 cells. CELL SIGNAL. 2020;75:109734.PubMedCrossRef
36.
Caiazza A, Russo L, Sabbatini M, Russo D. Hemodynamic and tubular changes induced by contrast media. BIOMED RES INT 2014, 2014:578974.
37.
Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. CLIN J AM SOC NEPHRO. 2008;3(1):288–96.CrossRef
38.
Dugbartey GJ, Redington AN. Prevention of contrast-induced nephropathy by limb ischemic preconditioning: underlying mechanisms and clinical effects. AM J PHYSIOL-RENAL. 2018;314(3):F319–28.CrossRef
39.
Wong PC, Li Z, Guo J, Zhang A. Pathophysiology of contrast-induced nephropathy. INT J CARDIOL. 2012;158(2):186–92.PubMedCrossRef
40.
Heyman SN, Brezis M, Epstein FH, Spokes K, Silva P, Rosen S. Early renal medullary hypoxic injury from radiocontrast and indomethacin. KIDNEY INT. 1991;40(4):632–42.PubMedCrossRef
41.
Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, Tsitsimpikou C, Tsatsakis A. Contrast-induced nephropathy: basic concepts, pathophysiological implications and prevention strategies. PHARMACOL THERAPEUT. 2017;180:99–112.CrossRef
42.
Bucher AM, De Cecco CN, Schoepf UJ, Meinel FG, Krazinski AW, Spearman JV, McQuiston AD, Wang R, Bucher J, Vogl TJ, et al. Is contrast medium osmolality a causal factor for contrast-induced nephropathy? BIOMED RES INT. 2014;2014:931413.PubMedPubMedCentralCrossRef
43.
Li Y, Ren K. The Mechanism of Contrast-Induced Acute Kidney Injury and Its Association with Diabetes Mellitus. CONTRAST MEDIA MOL I 2020, 2020:3295176.
44.
Dai H, Zhao C, Xiong Y, He Q, Su W, Li J, Yang Y, Lin R, Xiang S, Shao J. Evaluation of contrast-induced acute kidney injury using IVIM and DKI MRI in a rat model of diabetic nephropathy. INSIGHTS IMAGING. 2022;13(1):110.PubMedPubMedCentralCrossRef
45.
Pisani A, Riccio E, Andreucci M, Faga T, Ashour M, Di Nuzzi A, Mancini A, Sabbatini M. Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy. BIOMED RES INT 2013, 2013:868321.
46.
47.
Kanasaki K, Taduri G, Koya D. Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. FRONT ENDOCRINOL. 2013;4:7.CrossRef
48.
Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. IMMUNOL REV. 2008;223:20–38.PubMedCrossRef
49.
Pritchard AL, Hayward NK. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. CLIN CANCER RES. 2013;19(9):2301–9.PubMedCrossRef
50.
Lee HC, Sheu SH, Yen HW, Lai WT, Chang JG. JNK/ATF2 pathway is involved in iodinated contrast media-induced apoptosis. AM J NEPHROL. 2010;31(2):125–33.PubMedCrossRef
51.
52.
Hong YA, Bae SY, Ahn SY, Kim J, Kwon YJ, Jung WY, Ko GJ. Resveratrol ameliorates contrast Induced Nephropathy through the activation of SIRT1-PGC-1alpha-Foxo1 signaling in mice. KIDNEY BLOOD PRESS R. 2017;42(4):641–53.CrossRef
53.
54.
Zhang X, Ding M, Zhu P, Huang H, Zhuang Q, Shen J, Cai Y, Zhao M, He Q. New Insights into the Nrf-2/HO-1 Signaling Axis and Its Application in Pediatric Respiratory Diseases. OXID MED CELL LONGEV 2019, 2019:3214196.
55.
Tongqiang L, Shaopeng L, Xiaofang Y, Nana S, Xialian X, Jiachang H, Ting Z, Xiaoqiang D. Salvianolic Acid B Prevents Iodinated Contrast Media-Induced Acute Renal Injury in Rats via the PI3K/Akt/Nrf2 Pathway. OXID MED CELL LONGEV 2016, 2016:7079487.
56.
Goodman AI, Olszanecki R, Yang LM, Quan S, Li M, Omura S, Stec DE, Abraham NG. Heme oxygenase-1 protects against radiocontrast-induced acute kidney injury by regulating anti-apoptotic proteins. KIDNEY INT. 2007;72(8):945–53.PubMedCrossRef
57.
Zhao Z, Liao G, Zhou Q, Lv D, Holthfer H, Zou H. Sulforaphane Attenuates Contrast-Induced Nephropathy in Rats via Nrf2/HO-1 Pathway. OXID MED CELL LONGEV 2016, 2016:9825623.
58.
Keaney JJ, Hannon CM, Murray PT. Contrast-induced acute kidney injury: how much contrast is safe? NEPHROL DIAL TRANSPL. 2013;28(6):1376–83.CrossRef
59.
Liu ZZ, Schmerbach K, Lu Y, Perlewitz A, Nikitina T, Cantow K, Seeliger E, Persson PB, Patzak A, Liu R, et al. Iodinated contrast media cause direct tubular cell damage, leading to oxidative stress, low nitric oxide, and impairment of tubuloglomerular feedback. AM J PHYSIOL-RENAL. 2014;306(8):F864–72.CrossRef
60.
Liu Y, Liu YH, Tan N, Chen JY, Zhou YL, Li LW, Duan CY, Chen PY, Luo JF, Li HL, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention. PLoS ONE. 2014;9(10):e111124.PubMedPubMedCentralCrossRef
61.
Pattharanitima P, Tasanarong A. Pharmacological strategies to prevent contrast-induced acute kidney injury. BIOMED RES INT 2014, 2014:236930.
62.
Toruan M, Pranata R, Setianto BY, Haryana SM. The Role of MicroRNA in Contrast-Induced Nephropathy: A Scoping Review and Meta-Analysis. BIOMED RES INT 2020, 2020:4189621.
63.
Zhang Y, Chen X, Gueydan C, Han J. Plasma membrane changes during programmed cell deaths. CELL RES. 2018;28(1):9–21.PubMedCrossRef
64.
Ward DB, Valentovic MA. Contrast Induced Acute kidney Injury and direct cytotoxicity of Iodinated Radiocontrast Media on Renal Proximal Tubule cells. J PHARMACOL EXP THER. 2019;370(2):160–71.PubMedCrossRef
65.
Liu K, Hu C, Yin W, Zhou L, Gu X, Zuo X. An in vivo and in vitro model on the protective effect of cilnidipine on contrast-induced nephropathy via regulation of apoptosis and CaMKII/mPTP pathway. J BIOCHEM MOL TOXIC. 2023;37(1):e23238.CrossRef
66.
Komada T, Muruve DA. The role of inflammasomes in kidney disease. NAT REV NEPHROL. 2019;15(8):501–20.PubMedCrossRef
67.
Xiao S, Zhang J, Dong W, Jiang D, Yang K. Pyroptosis: a type of cell death associated with inflammation. Chem life. 2017;37(03):423–8.
68.
69.
Li N, Zhao T, Cao Y, Zhang H, Peng L, Wang Y, Zhou X, Wang Q, Li J, Yan M, et al. Tangshen Formula attenuates Diabetic kidney Injury by Imparting Anti-pyroptotic effects via the TXNIP-NLRP3-GSDMD Axis. FRONT PHARMACOL. 2020;11:623489.PubMedCrossRef
70.
Zhu X, Li S, Lin Q, Shao X, Wu J, Zhang W, Cai H, Zhou W, Jiang N, Zhang Z, et al. alphaKlotho protein has therapeutic activity in contrast-induced acute kidney injury by limiting NLRP3 inflammasome-mediated pyroptosis and promoting autophagy. PHARMACOL RES. 2021;167:105531.PubMedCrossRef
71.
Chen F, Lu J, Yang X, Xiao B, Chen H, Pei W, Jin Y, Wang M, Li Y, Zhang J et al. Acetylbritannilactone attenuates contrast-induced acute kidney injury through its anti-pyroptosis effects. BIOSCIENCE REP 2020, 40(2).
72.
Aglietti RA, Estevez A, Gupta A, Ramirez MG, Liu PS, Kayagaki N, Ciferri C, Dixit VM, Dueber EC. GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. P NATL ACAD SCI USA. 2016;113(28):7858–63.CrossRef
73.
Zhang Z, Shao X, Jiang N, Mou S, Gu L, Li S, Lin Q, He Y, Zhang M, Zhou W, et al. Caspase-11-mediated tubular epithelial pyroptosis underlies contrast-induced acute kidney injury. CELL DEATH DIS. 2018;9(10):983.PubMedPubMedCentralCrossRef
74.
Lin Q, Ni Z. Research progress of mitochondrial autophagy in kidney diseases. China Blood Purif. 2018;18(03):197–200.
75.
Emma F, Montini G, Parikh SM, Salviati L. Mitochondrial dysfunction in inherited renal disease and acute kidney injury. NAT REV NEPHROL. 2016;12(5):267–80.PubMedPubMedCentralCrossRef
76.
77.
Lei R, Zhao F, Tang CY, Luo M, Yang SK, Cheng W, Li XW, Duan SB. Mitophagy plays a protective role in Iodinated contrast-Induced Acute Renal tubular epithelial cells Injury. Cell Physiol Biochem. 2018;46(3):975–85.PubMedCrossRef
78.
Cheng W, Zhao F, Tang CY, Li XW, Luo M, Duan SB. Comparison of iohexol and iodixanol induced nephrotoxicity, mitochondrial damage and mitophagy in a new contrast-induced acute kidney injury rat model. ARCH TOXICOL. 2018;92(7):2245–57.PubMedCrossRef
79.
Lin Q, Li S, Jiang N, Shao X, Zhang M, Jin H, Zhang Z, Shen J, Zhou Y, Zhou W, et al. PINK1-parkin pathway of mitophagy protects against contrast-induced acute kidney injury via decreasing mitochondrial ROS and NLRP3 inflammasome activation. REDOX BIOL. 2019;26:101254.PubMedPubMedCentralCrossRef
80.
Yang X, Yan X, Yang D, Zhou J, Song J, Yang D. Rapamycin attenuates mitochondrial injury and renal tubular cell apoptosis in experimental contrast-induced acute kidney injury in rats. BIOSCIENCE REP 2018, 38(6).
81.
Al-Shawadfy MG, Kamel G, Abd-Allah A. Crosstalk among apoptosis, inflammation, and autophagy in relation to melatonin protective effect against contrast-induced nephropathy in rats. CAN J PHYSIOL PHARM. 2022;100(9):858–67.CrossRef
82.
Ko GJ, Bae SY, Hong YA, Pyo HJ, Kwon YJ. Radiocontrast-induced nephropathy is attenuated by autophagy through regulation of apoptosis and inflammation. HUM EXP TOXICOL. 2016;35(7):724–36.PubMedCrossRef
83.
Dragomir MP, Knutsen E, Calin GA. SnapShot: unconventional miRNA functions. Cell. 2018;174(4):1038.PubMedCrossRef
84.
85.
Gutierrez-Escolano A, Santacruz-Vazquez E, Gomez-Perez F. Dysregulated microRNAs involved in contrast-induced acute kidney injury in rat and human. Ren Fail. 2015;37(9):1498–506.PubMedCrossRef
86.
Liu Y, Liu B, Liu Y, Chen S, Yang J, Liu J, Sun G, Bei WJ, Wang K, Chen Z, et al. MicroRNA expression profile by next-generation sequencing in a novel rat model of contrast-induced acute kidney injury. ANN TRANSL MED. 2019;7(8):178.PubMedPubMedCentralCrossRef
87.
Liu B, Chai Y, Guo W, Lin K, Chen S, Liu J, Sun G, Chen G, Song F, He Y, et al. MicroRNA-188 aggravates contrast-induced apoptosis by targeting SRSF7 in novel isotonic contrast-induced acute kidney injury rat models and renal tubular epithelial cells. ANN TRANSL MED. 2019;7(16):378.PubMedPubMedCentralCrossRef
88.
Niu HM, Guo LQ, Qiao YH, Jiao HY. MiR-429 prohibited NF-kappaB signalling to alleviate contrast-induced acute kidney injury via targeting PDCD4. AUTOIMMUNITY 2021, 54(5):243–253.
89.
Liu X, Li Q, Sun L, Chen L, Li Y, Huang B, Liu Y, Jiang C. miR-30e-5p regulates autophagy and apoptosis by targeting Beclin1 involved in contrast-induced acute kidney Injury. CURR MED CHEM. 2021;28(38):7974–84.PubMedCrossRef
90.
Xu J, Ma L, Fu P. MicroRNA-30c attenuates contrast-induced acute kidney injury by suppressing NLRP3 inflammasome. INT IMMUNOPHARMACOL. 2020;87:106457.PubMedCrossRef
91.
Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. MED RES REV. 2012;32(2):326–48.PubMedCrossRef
92.
Sun SQ, Zhang T, Ding D, Zhang WF, Wang XL, Sun Z, Hu LH, Qin SY, Shen LH, He B. Circulating MicroRNA-188, -30a, and– 30e as early biomarkers for contrast-Induced Acute kidney Injury. J AM HEART ASSOC 2016, 5(8).
93.
Kodzwa R. ACR Manual on contrast media: 2018 updates. RADIOL TECHNOL. 2019;91(1):97–100.PubMed
94.
Morabito S, Pistolesi V, Benedetti G, Di Roma A, Colantonio R, Mancone M, Sardella G, Cibelli L, Ambrosino M, Polistena F, et al. Incidence of contrast-induced acute kidney injury associated with diagnostic or interventional coronary angiography. J NEPHROL. 2012;25(6):1098–107.PubMedCrossRef
95.
Wu MJ, Tsai SF, Lee CT, Wu CY. The predictive value of Hyperuricemia on Renal Outcome after contrast-enhanced computerized tomography. J CLIN MED 2019, 8(7).
96.
Eng J, Wilson RF, Subramaniam RM, Zhang A, Suarez-Cuervo C, Turban S, Choi MJ, Sherrod C, Hutfless S, Iyoha EE, et al. Comparative effect of contrast media type on the incidence of contrast-Induced Nephropathy: a systematic review and Meta-analysis. ANN INTERN MED. 2016;164(6):417–24.PubMedCrossRef
97.
Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993;188(1):171–8.PubMedCrossRef
98.
Azzalini L, Poletti E, Lombardo F, Laricchia A, Beneduce A, Moscardelli S, Bellini B, Maccagni D, Cappelletti A, Ancona MB, et al. Risk of contrast-induced nephropathy in patients undergoing complex percutaneous coronary intervention. INT J CARDIOL. 2019;290:59–63.PubMedCrossRef
99.
Balemans CE, Reichert LJ, van Schelven BI, van den Brand JA, Wetzels JF. Epidemiology of contrast material-induced nephropathy in the era of hydration. Radiology. 2012;263(3):706–13.PubMedCrossRef
100.
Moore A, Dickerson E, Dillman JR, Vummidi D, Kershaw DB, Khalatbari S, Davenport MS. Incidence of nonconfounded post-computed tomography acute kidney injury in hospitalized patients with stable renal function receiving intravenous iodinated contrast material. CURR PROBL DIAGN RAD. 2014;43(5):237–41.CrossRef
101.
(2016) > Official release. Chinese Journal of Interventional Cardiology. 2016;24(06):315.
102.
Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA, Chertow GM, Bhatt DL, Shunk K, et al. Outcomes after angiography with sodium bicarbonate and Acetylcysteine. NEW ENGL J MED. 2018;378(7):603–14.PubMedCrossRef
103.
Biernacka-Fialkowska B, Szuksztul M, Suslik W, Dzierwa K, Tekieli L, Kostkiewicz M, Podolec P, Pieniazek P. Intravenous N-acetylcysteine for the PRevention of contrast-induced nephropathy - a prospective, single-center, randomized, placebo-controlled trial. The INPROC trial. POSTEP KARDIOL INTER. 2018;14(1):59–66.
104.
Kang X, Hu DY, Li CB, Ai ZS, Peng A. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis. Ren Fail. 2015;37(10):297–303.PubMedCrossRef
105.
Palli E, Makris D, Papanikolaou J, Garoufalis G, Tsilioni I, Zygoulis P, Zakynthinos E. The impact of N-acetylcysteine and ascorbic acid in contrast-induced nephropathy in critical care patients: an open-label randomized controlled study. CRIT CARE. 2017;21(1):269.PubMedPubMedCentralCrossRef
106.
Gandhi S, Mosleh W, Abdel-Qadir H, Farkouh ME. Statins and contrast-induced acute kidney injury with coronary angiography. AM J MED. 2014;127(10):987–1000.PubMedCrossRef
107.
Vanmassenhove J, Vanholder R, Lameire N. Statins for the prevention of contrast-induced acute kidney injury. CURR OPIN NEPHROL HY. 2016;25(6):508–17.CrossRef
108.
Giacoppo D, Capodanno D, Capranzano P, Aruta P, Tamburino C. Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. AM J CARDIOL. 2014;114(4):541–8.PubMedCrossRef
109.
van Baar M, van Ruiten CC, Muskiet M, van Bloemendaal L, IJzerman RG, van Raalte DH. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care. 2018;41(8):1543–56.PubMedCrossRef
110.
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. NAT REV CARDIOL. 2020;17(12):761–72.PubMedCrossRef
111.
Nusca A, Tuccinardi D, Pieralice S, Giannone S, Carpenito M, Monte L, Watanabe M, Cavallari I, Maddaloni E, Ussia GP, et al. Platelet effects of anti-diabetic therapies: New perspectives in the management of patients with diabetes and Cardiovascular Disease. FRONT PHARMACOL. 2021;12:670155.PubMedPubMedCentralCrossRef
112.
Huang X, Guo X, Yan G, Zhang Y, Yao Y, Qiao Y, Wang D, Chen G, Zhang W, Tang C, et al. Dapagliflozin attenuates contrast-induced acute kidney Injury by regulating the HIF-1alpha/HE4/NF-kappaB pathway. J CARDIOVASC PHARM. 2022;79(6):904–13.CrossRef
113.
Kultursay B, Yilmaz C, Guven B, Mutlu D, Karagoz A. Potential renoprotective effect of SGLT2 inhibitors against contrast-induced AKI in diabetic STEMI patients undergoing primary PCI. KARDIOL POL. 2024;82(1):29–36.PubMedCrossRef
114.
Komiyama K, Ashikaga T, Inagaki D, Miyabe T, Arai M, Yoshida K, Miyazawa S, Nakada A, Kawamura I, Masuda S, et al. Sodium bicarbonate-ascorbic acid combination for Prevention of contrast-Induced Nephropathy in chronic kidney disease patients undergoing catheterization. CIRC J. 2017;81(2):235–40.PubMedCrossRef
115.
Xu Y, Zheng X, Liang B, Gao J, Gu Z. Vitamins for Prevention of contrast-induced acute kidney Injury: a systematic review and Trial Sequential Analysis. AM J CARDIOVASC DRUG. 2018;18(5):373–86.CrossRef
116.
Arabmomeni M, Najafian J, Abdar EM, Samadi M, Mirbagher L. Comparison between theophylline, N-acetylcysteine, and theophylline plus N-acetylcysteine for the prevention of contrast-induced nephropathy. ARYA ATHEROSCLER. 2015;11(1):43–9.PubMedPubMedCentral
117.
Dai B, Liu Y, Fu L, Li Y, Zhang J, Mei C. Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. AM J KIDNEY DIS. 2012;60(3):360–70.PubMedCrossRef
118.
Huber W, Huber T, Baum S, Franzen M, Schmidt C, Stadlbauer T, Beitz A, Schmid RM, Schmid S. Sodium bicarbonate prevents contrast-Induced Nephropathy in Addition to Theophylline: a Randomized Controlled Trial. Medicine. 2016;95(21):e3720.PubMedPubMedCentralCrossRef
Metadata
Title
Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment
Authors
Yanyan Li
Junda Wang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2024
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-024-03570-6

Other articles of this Issue 1/2024

BMC Nephrology 1/2024 Go to the issue

Case Report

An unusual case of adult-onset still’s disease complicated with anti-complement factor H antibodies associated atypical haemolytic uraemic syndrome

Research

The kidney histopathological spectrum of patients with kidney injury following snakebite envenomation in India: scoping review of five decades

Case Report

Fruquintinib-induced renal-limited thrombotic microangiopathy: a case report

Research

Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study

Research

Global variations in funding and use of hemodialysis accesses: an international report using the ISN Global Kidney Health Atlas

Research

Improvement effects of transplanting pancreatic islet that previously incubated with biomaterials on the diabetic nephropathy in STZ- diabetic rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits